Press release from Companies

Publicerat: 2026-01-28 11:00:00

Micropos Medical AB: St Luke’s Hospital in Dublin starts ASBRT Treatments Using Raypilot System

Treatment with ASBRT (Augmented Stereotactic Body Radiotherapy) and the Raypilot® System has now begun at St Luke’s Hospital in Dublin. Last Friday, the treatment of the first patient was successfully completed with a team from Micropos Medical present on site.

As previously announced, St Luke’s Hospital has entered into a rental agreement for the Raypilot System in order to evaluate the technology while integrating five-fraction SBRT into its daily clinical workflow. The objective is for ASBRT to become part of the standard treatment for prostate cancer at the clinic.

Dr Alex Boychak, Radiation Oncologist in charge at the Dublin clinic, is very pleased and comments:

"With the Raypilot System, we can see exactly where we are delivering the radiation. Being able to deliver the dose in the right place at the right time gives us confidence in the treatment. Above all, this allows our patients to benefit from a safe, modern and efficient treatment method with a reduced risk of side effects."

Highlighting patient benefits of modern radiotherapy
Micropos Medical is actively working to raise awareness of modern radiotherapy as a relevant treatment option for prostate cancer, offering advantages for both patients and healthcare providers.

"There is now substantial evidence that modern radiotherapy is a safe and effective prostate cancer treatment, providing significant benefits for patients. We want to increase knowledge and awareness of this. For us, the start at St Luke’s Hospital represents an important milestone, and we are pleased to see ASBRT begin to be adopted as a standard treatment. The more patients who gain access to this method, the better," says Richard Forsberg, CEO of Micropos Medical.

For more information, contact:

Richard Forsberg, CEO
Micropos Medical AB
Phone: 031-760 80 05
E-mail: richard.forsberg@micropos.se

Micropos Medical AB is a Swedish medical device company that develops, manufactures, and sells technology enabling enhanced radiotherapy cancer treatment. The Raypilot® System, the product from the company, generates high precision as well as high efficiency through real-time tumour tracking in radiation treatment of prostate cancer. Using The Raypilot System, clinics can treat their patients with accuracy and reduced risk of damaging healthy tissue surrounding the tumour. The company is listed on the Spotlight Stock Market. www.micropos.se

Läs mer hos Cision
Läs mer om Micropos Medical AB